DERMATOLOGY EDITION

Risankizumab in Adults with Psoriatic Arthritis

Explore risankizumab for Psoriatic arthritis: Beyond ACR, it significantly improves enthesitis, dactylitis, and QoL scores like HAQ-DI. Promising in efficacy and safety, with full 208-week study results anticipated for a complete understanding.

FAMILY PRACTICE

Advertisement

STL - image

Newsletter & Free PDF with Latest Articles

From STL Archives:

Popular